兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300573 兴齐眼药

已收盘 04-29 15:00:00

{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":258.17,"timestamp":1714374192000,"preClose":261.6,"halted":0,"volume":3696547,"delay":0,"floatShares":95706500,"shares":125000000,"eps":2.0503,"marketStatus":"已收盘","marketStatusCode":5,"change":-3.43,"latestTime":"04-29 15:00:00","open":264.59,"high":266.49,"low":254.13,"amount":958000000,"amplitude":0.0472,"askPrice":258.17,"askSize":9,"bidPrice":258.14,"bidSize":1,"shortable":0,"etf":0,"ttmEps":2.0503,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714440600000},"adr":0,"adjPreClose":261.6,"symbolType":"stock","openAndCloseTimeList":[[1714354200000,1714361400000],[1714366800000,1714374000000]],"highLimit":287.76,"lowLimit":235.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":124589194,"pbRate":18.77,"roa":"--","roe":"2.03%","epsLYR":1.93,"committee":-0.087719,"marketValue":32165000000,"floatMarketCap":24709000000,"peRate":125.918166,"changeRate":-0.0131,"turnoverRate":0.0386,"status":1},"requestUrl":"/m/hq/s/300573/tweets","defaultTab":"tweets","newsList":[{"id":"2430760044","title":"图解兴齐眼药一季报：第一季度单季净利润同比增79.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430760044","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430760044?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:24","pubTimestamp":1714037096,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药2024年一季报显示，公司主营收入3.5亿元，同比上升22.1%；归母净利润3474.9万元，同比上升79.59%；扣非净利润3524.1万元，同比上升126.46%；负债率18.22%，财务费用-119.43万元，毛利率76.1%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500036456.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430476508","title":"兴齐眼药(300573)3月31日股东户数1.57万户，较上期增加48.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430476508","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430476508?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:18","pubTimestamp":1714036704,"startTime":"0","endTime":"0","summary":"证券之星消息，近日兴齐眼药披露，截至2024年3月31日公司股东户数为1.57万户，较12月31日增加5164.0户，增幅为48.83%。在化学制药行业个股中，兴齐眼药股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.33万户。从股价来看，2023年12月31日至2024年3月31日，兴齐眼药区间涨幅为17.38%，在此期间股东户数增加5164.0户，增幅为48.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500036008.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430942095","title":"兴齐眼药最新公告：一季度净利润同比增长79.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430942095","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430942095?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:24","pubTimestamp":1714033442,"startTime":"0","endTime":"0","summary":"兴齐眼药披露第一季度报告，2024年一季度净利润3475万元，同比增长79.59%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500032647.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430422548","title":"兴齐眼药(300573.SZ)发布一季度业绩，净利润3474.9万元，增长79.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430422548","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430422548?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:55","pubTimestamp":1714031704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布2024年第一季度报告，该公司营业收入为3.5亿元，同比增长22.10%。归属于上市公司股东的净利润为3474.9万元，同比增长79.59%。归属于上市公司股东的扣除非经常性损益的净利润为3524.1万元，同比增长126.46%。基本每股收益为0.28元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109673.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430941943","title":"兴齐眼药（300573）4月24日主力资金净买入5026.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430941943","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430941943?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:14","pubTimestamp":1714007650,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月24日收盘，兴齐眼药报收于245.3元，上涨5.96%，换手率4.65%，成交量4.45万手，成交额10.69亿元。4月24日的资金流向数据方面，主力资金净流入5026.1万元，占总成交额4.7%，游资资金净流入3631.11万元，占总成交额3.4%，散户资金净流出8657.21万元，占总成交额8.1%。融券方面，融券卖出1.48万股，融券偿还1.0万股，融券余量10.34万股，融券余额2535.74万元。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500018031.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429945498","title":"兴齐眼药：公司将结合市场需求，科学规划产能及调配生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945498","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429945498?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:02","pubTimestamp":1713780140,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)04月22日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘：关于公司低阿产能，除了去年准备的1.2亿只/年的产能，以及目前正在规划实施的1.8亿支/年的新药一期项目，公司目前还有其它关于低阿的产能规划吗？谢谢！兴齐眼药董秘：尊敬的投资者您好，公司将结合市场需求，科学规划产能及调配生产，感谢您的关注。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200021448.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428864554","title":"兴齐眼药：2023年净利2.4亿元 同比增13.39% 拟10转增4派30元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428864554","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2428864554?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:14","pubTimestamp":1713428040,"startTime":"0","endTime":"0","summary":"格隆汇4月18日｜兴齐眼药公告，2023年度净利润2.4亿元，同比增加13.39%，向全体股东每10股派发现金红利30元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增4股。               \n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-18/doc-inasfvuy6456148.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-18/doc-inasfvuy6456148.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428551356","title":"兴齐眼药(300573.SZ)发2023年度业绩，净利润2.40亿元，同比增长13.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428551356","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428551356?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:13","pubTimestamp":1713427980,"startTime":"0","endTime":"0","summary":"兴齐眼药发布2023年年度报告，报告期内公司实现营业收入14.68亿元，同比增长17.42%;归属于上市公司股东的净利润2.40亿元，同比增长13.39%;归属于上市公司股东扣除非经常性损益净利润2.40亿元，同比增长15.59%;基本每股收益1.93元/股。2024年3月，公司硫酸阿托品滴眼液获得国家药品监督管理局签发的《药品注册证书》，目前国内尚无近视相关适应症的同类产品上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inasfvuv0767833.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inasfvuv0767833.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418384566","title":"兴齐眼药(300573.SZ)获硫酸阿托品滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2418384566","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2418384566?lang=zh_cn&edition=full","pubTime":"2024-03-11 15:57","pubTimestamp":1710143820,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)发布公告，公司收到国家药品监督管理局核准签发的硫酸阿托品滴眼液《药品注册证书》。据悉，本品是以硫酸阿托品为活性成分的眼用制剂，获批临床适应症为：本品用于延缓球镜度数为-1.00D至-4.00D(散光≤1.50D、屈光参差≤1.50D)的6至12岁儿童的近视进展。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-11/doc-inamxtki8818760.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-11/doc-inamxtki8818760.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2416461987","title":"眼药水也能“硬战”百亿抗ED药物市场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2416461987","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2416461987?lang=zh_cn&edition=full","pubTime":"2024-03-01 19:56","pubTimestamp":1709294219,"startTime":"0","endTime":"0","summary":"发病人数渐增下，ED药物市场规模也随之扩大。百亿市场的前景之下，ED药物赛道可谓吸引，未来一旦确定毛果芸香碱对ED相关病症治疗有效，那么定将在资本市场上掀起一阵“狂风暴雨”，A股及港股市场上的眼药水公司也将收获利好。NVK002现有望成为全球首款经临床验证可延缓青少年及儿童近视加深的认可药品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1080336.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2380725656","title":"兴齐眼药增收不增利 前三季度利润端首次出现负增长 | 数说三季报","url":"https://stock-news.laohu8.com/highlight/detail?id=2380725656","media":"新浪证券","top":-1,"share":"https://www.laohu8.com/m/news/2380725656?lang=zh_cn&edition=full","pubTime":"2023-11-01 16:36","pubTimestamp":1698827760,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！报告显示，兴齐眼药2023年前三季度增收不增利，实现营业收入共11.05亿元，同比增长10.02%；实现利润总额2.03亿元，同比下降14.64%，实现归母净利润1.82亿元，同比下降10.11%。这也是2019年以来，兴齐眼药前三季度利润端首次出现负增长。　　销售毛利率由2022年同期的80.13%下降至当期的77.58%。偿债能力方面，兴齐眼药2023年前三季度速动比率由2022年同期的4.06下降至2.9，偿债能力减弱。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/med/2023-11-01/doc-imztccqs5727725.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/med/2023-11-01/doc-imztccqs5727725.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","stockEarnings":[{"period":"1week","weight":0.1897},{"period":"1month","weight":0.2064},{"period":"3month","weight":0.7119},{"period":"6month","weight":0.576},{"period":"1year","weight":1.0831},{"period":"ytd","weight":0.416}],"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","perCapita":"6080股","boardName":"医药制造业","registeredCapital":"12458万元","compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0236},{"period":"3month","weight":0.0998},{"period":"6month","weight":0.0298},{"period":"1year","weight":-0.0633},{"period":"ytd","weight":0.0464}],"survey":"　　沈阳兴齐眼药股份有限公司专注于眼科药物领域,是一家主要从事眼科药物研发、生产、销售的专业企业,主要产品是眼科处方药物。以“兹润”、“速高捷”、“迪友”、“迪非”、“兹养”等产品为代表的眼用制剂产品已在行业内树立了良好的品牌声誉。公司多项产品被认定为国家重点新产品、省名牌产品、省优秀新产品、省质量名优产品。","serverTime":1714434541231,"listedPrice":5.16,"stockholders":"15740人(较上一季度增加48.83%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}